Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

Trial Profile

Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Etoposide; Ifosfamide
  • Indications Osteosarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (n=23) from the single-agent lenvatinib dose-finding part of a phase 1/2 study in children and adolescents with solid tumors presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2017 Data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2017, according to an Eisai Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top